缬沙坦对血液透析患者血钾的影响  

Effects of valsartan on the impact of potassium in hemodialysis patients

作　　者：安鑫[1] 刘燕[1] 

机构地区：[1]新疆维吾尔自治区克拉玛依市中心医院,新疆克拉玛依834000

出　　处：《中国现代医生》2012年第3期159-160,共2页China Modern Doctor

摘　　要：目的探讨缬沙坦对血液透析患者血钾的影响。方法肾衰竭血液透析患者80例平分为两组,治疗组与对照组各40例,两组均采用血液透析治疗,治疗组在透析治疗的基础上服用缬沙坦分散片。结果两组治疗前的血钾水平分别为(6.5±2.3)mmol/L和(6.9±2.2)mmol/L;治疗后对照组血钾为(10.8±3.3)mmol/L,治疗组为(6.8±1.2)mmol/L,表明治疗前两组血钾对比无明显差异(t=1.253,P>0.05),治疗后治疗组血钾水平明显低于对照组(t=5.963,P<0.05)。结论缬沙坦应用于血液透析患者能在维持疗效的基础上,无升高血钾作用,从而提高保护效果,值得推广应用。Objective To investigate the effect of of valsartan on the impact of potassium in hemodialysis patients. Methods Eighty patients with renal failure hemodialysis patients were equally divided into two groups-the hemodialysis treatment, the treatment group were added the va]sartan treatment. Results The serum potassium in the wo groups before treatment were （6.5±2.3） mmol/L and （6.9±2.2） mmol/L, after treatment, the serum potassium of the the control group was （10.8±3.3） mmol/L, so that was （6.8±1.2） mmol/L in the treatment group, the two groups before treatment showed no difference （t=1.253, P 〉 0.05）, after treatment, the serum potassium levels of the treatment group were significantly lower than the control group （t=5.963, P〈O.05）. Conclusion Valsartan can keep the efficacy that be used for hemodialysis patients, and has role of no rise hyperkalemia, thereby enhance the protective effect, should be widely applied.

关 键 词：缬沙坦 血液透析 血钾 

分 类 号：R459.5[医药卫生—治疗学]